Literature DB >> 6351113

Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

F M Schabel, D P Griswold, T H Corbett, W R Laster.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6351113     DOI： 10.1016/0163-7258(83)90042-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  10 in total

1.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 4.  The rationale of dose-response curves in selecting cancer drug dosing.

Authors:  Jennifer H Martin; Simon Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-06-20       Impact factor: 4.335

5.  Influence of scheduling on two-drug combinations of alkylating agents in vivo.

Authors:  B A Teicher; S A Holden; S M Jones; J P Eder; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.

Authors:  G Milano; M Namer; J L Boublil; R Khater; M Frenay; A Thyss; J Bourry; C Philip; N Renée; J N Bruneton
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.

Authors:  J L Fischel; P Formento; M Berlion; J Berille; J Gioanni; J P Bizzari; G Milano
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Authors:  E Frei; S A Holden; R Gonin; D J Waxman; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.

Authors:  K S Smith; B A Folz; E G Adams; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.

Authors:  J L Boublil; G Milano; R Khater; J Bourry; A Thyss; J N Bruneton; N Renée; C Philip; M Namer
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.